We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$18.6M
Cap. Flow
+$5.56M
Cap. Flow %
1.53%
Top 10 Hldgs %
25.94%
Holding
173
New
49
Increased
12
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$20.1M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.18M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.64M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.41M
5
QDEL icon
QuidelOrtho
QDEL
+$5.15M

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$7.59M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.09M
3
CDNA icon
CareDx
CDNA
+$5.7M
4
HAE icon
Haemonetics
HAE
+$5.22M
5
LITS
Lite Strategy Inc
LITS
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 7.92%
3 Technology 1.93%
4 Industrials 1.24%
5 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLMN icon
76
Hillman Solutions
HLMN
$1.79B
$1.53M 0.42%
142,000
– –
ADRT.U
77
DELISTED
Ault Disruptive Technologies Corporation Units, each consisting of one share of Common Stock, and three-fourths of one Redeemable Warrant to purchase one share of Common Stock
ADRT.U
$1.52M 0.42%
+150,000
New +$1.51M
FLUX icon
78
Flux Power
FLUX
$11.4M
$1.49M 0.41%
346,268
-175,704
-34% -$934K
KALV
79
DELISTED
KalVista Pharmaceuticals
KALV
$1.48M 0.41%
111,834
– –
SDOT icon
80
Sadot Group
SDOT
$12.4M
$1.44M 0.4%
+998
New +$2.15M
SYRE icon
81
Spyre Therapeutics
SYRE
$9.2B
$1.4M 0.38%
11,751
-12,637
-52% -$1.99M
EIGR
82
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.35M 0.37%
8,700
+2,117
+32% +$409K
CNTX icon
83
Context Therapeutics
CNTX
$44.8M
$1.31M 0.36%
+493,531
New +$2.46M
BURU
84
DELISTED
NUBURU INC
BURU
$1.26M 0.35%
643
– –
QNGY
85
DELISTED
Quanergy Systems, Inc.
QNGY
$1.11M 0.31%
5,560
– –
RZLT icon
86
Rezolute
RZLT
$442M
$1.1M 0.3%
+230,000
New +$1.34M
FRGE
87
DELISTED
Forge Global Holdings
FRGE
$1M 0.28%
6,807
– –
OHAAU
88
DELISTED
OPY Acquisition Corp. I Units
OHAAU
$1M 0.28%
+100,000
New +$998K
ARYD
89
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$992K 0.27%
+100,000
New +$995K
AXH
90
DELISTED
Industrial Human Capital, Inc.
AXH
$992K 0.27%
+100,000
New +$990K
FMAC
91
DELISTED
FirstMark Horizon Acquisition Corp.
FMAC
$989K 0.27%
100,000
– –
BLSA
92
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$980K 0.27%
100,000
– –
OMEG
93
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$977K 0.27%
100,000
– –
ACHV icon
94
Achieve Life Sciences
ACHV
$679M
$949K 0.26%
122,000
– –
DDI
95
DoubleDown Interactive
DDI
$592M
$944K 0.26%
60,876
-99,124
-62% -$1.6M
BBIO icon
96
CALL
BridgeBio Pharma
BBIO
$16.6B
$906K 0.25%
+54,300
New +$2.3M
CNTB
97
Connect Biopharma Holdings
CNTB
$140M
$901K 0.25%
+175,000
New +$1.95M
VRCA icon
98
Verrica Pharmaceuticals
VRCA
$90.4M
$897K 0.25%
9,789
-15,835
-62% -$1.79M
MITA
99
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
$826K 0.23%
85,000
– –
SNAX
100
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
$640K 0.18%
10,808
-2,525
-19% -$181K
2 3
4
5 6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Altium Capital Management held 173 positions worth $363M, down 4.9% from $381M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Altium Capital Management's Q4 2021 filing shows 49 new, 12 increased, 23 reduced and 40 closed positions. Its largest new stake was Esperion Therapeutics: 2,515,785 shares worth $12.6M. The largest sale was Aldeyra Therapeutics, an estimated $7.59M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Technology.

  • Altium Capital Management's largest Q4 2021 buy was Esperion Therapeutics: 2,515,785 shares worth $12.6M.
  • Altium Capital Management added most to Bicycle Therapeutics in Q4 2021, an estimated $4.41M increase.
  • Altium Capital Management's biggest Q4 2021 reduction was Cerus, cutting an estimated $4.27M.
  • Altium Capital Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $7.59M.
  • Altium Capital Management's ten largest holdings make up 26% of its $363M portfolio in Q4 2021.
  • Altium Capital Management opened 49 new positions and closed 40 in Q4 2021.
  • Altium Capital Management's portfolio value fell 4.9% quarter-over-quarter to $363M.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.